Vivesto AB develops, produces, markets, and sells drugs in the field of human and veterinary oncology in Sweden. Its lead product is Apealea (paclitaxel micellar) for the treatment of ovarian cancer. The company's products portfolio includes Docetaxel micellar, a patented formulation that combines cytotoxin docetaxel with XR-17, which is in Phase 1b clinical trial for the treatment of prostate cancer; and Cantrixil to treat ovarian cancer. its animal health product portfolio includes Paccal Vet, a formulation of paclitaxel with its XR-17 encapsulation technology for the treatment of canine mastocytoma; and Doxophos Vet, a patented formulation of doxorubicin to treat lymphoma. The company was formerly known as Oasmia Pharmaceutical AB (publ) and changed its name to Vivesto AB in March 2022. Vivesto AB was incorporated in 1988 and is headquartered in Solna, Sweden.
| 0.0499 | |
| 0.0499 | |
| - | |
| 0.0499 | |
| 0.0499 | |
| 0.0002-0.05 | |
| 13 448 K | |
| 179 M | |
| 6 612 K | |
| -0.0045 | |
| 0.631 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
Kazia Therapeutics Ltd (NASDAQ: KZIA) has entered an exclusive worldwide licensing agreement with Oasmia Pharmaceutical AB (OTCMKTS: OASMY) for Cantrixil under development the treatment of ovarian can...
Kazia Therapeutics Ltd (NASDAQ: KZIA) has entered an exclusive worldwide licensing agreement with Oasmia Pharmaceutical AB (OTCMKTS: OASMY) for Cantrixil under development the treatment of ovarian can...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
